Abstract
At the highly anticipated session at JADPRO Live 2024, Oxana Megherea, PharmD, BCOP, covered several newly approved therapies for patients with multiple myeloma, leukemia, lymphoma, and other hematologic malignancies, including their mechanisms of action and strategies for managing adverse events.
